Dynamics of clonal evolution in myelodysplastic syndromes H Makishima, T Yoshizato, K Yoshida, MA Sekeres, T Radivoyevitch, ... Nature genetics 49 (2), 204-212, 2017 | 444 | 2017 |
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms L Palomo, M Meggendorfer, S Hutter, S Twardziok, V Ademà, I Fuhrmann, ... Blood, The Journal of the American Society of Hematology 136 (16), 1851-1862, 2020 | 139 | 2020 |
Personalized prediction model to risk stratify patients with myelodysplastic syndromes A Nazha, R Komrokji, M Meggendorfer, X Jia, N Radakovich, J Shreve, ... Journal of Clinical Oncology 39 (33), 3737-3746, 2021 | 119 | 2021 |
Genomic determinants of chronic myelomonocytic leukemia BJ Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, ... Leukemia 31 (12), 2815-2823, 2017 | 103 | 2017 |
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL) SR Sanikommu, MJ Clemente, P Chomczynski, MG Afable, A Jerez, ... Leukemia & lymphoma 59 (2), 416-422, 2018 | 99 | 2018 |
Rational management approach to pure red cell aplasia SK Balasubramanian, M Sadaps, S Thota, M Aly, BP Przychodzen, ... Haematologica 103 (2), 221, 2018 | 80 | 2018 |
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes A Nazha, K Al-Issa, BK Hamilton, T Radivoyevitch, AT Gerds, S Mukherjee, ... Leukemia 31 (12), 2848-2850, 2017 | 69 | 2017 |
Origins of myelodysplastic syndromes after aplastic anemia E Negoro, Y Nagata, MJ Clemente, N Hosono, W Shen, A Nazha, ... Blood, The Journal of the American Society of Hematology 130 (17), 1953-1957, 2017 | 69 | 2017 |
Consequences of mutant TET2 on clonality and subclonal hierarchy CM Hirsch, A Nazha, K Kneen, ME Abazeed, M Meggendorfer, ... Leukemia 32 (8), 1751-1761, 2018 | 65 | 2018 |
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes Y Nagata, R Zhao, H Awada, CM Kerr, I Mirzaev, S Kongkiatkamon, ... Blood, The Journal of the American Society of Hematology 136 (20), 2249-2262, 2020 | 64 | 2020 |
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes Y Nagata, H Makishima, CM Kerr, BP Przychodzen, M Aly, A Goyal, ... Nature communications 10 (1), 5386, 2019 | 59 | 2019 |
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia S Lundgren, MAI Keränen, M Kankainen, J Huuhtanen, G Walldin, ... Leukemia 35 (5), 1365-1379, 2021 | 56 | 2021 |
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes Y Nagata, S Narumi, Y Guan, BP Przychodzen, CM Hirsch, H Makishima, ... Blood, The Journal of the American Society of Hematology 132 (21), 2309-2313, 2018 | 56 | 2018 |
Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence A Nazha, MA Sekeres, R Bejar, MJ Rauh, M Othus, RS Komrokji, ... JCO precision oncology 3, 1-11, 2019 | 55 | 2019 |
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia H Awada, A Durmaz, C Gurnari, A Kishtagari, M Meggendorfer, CM Kerr, ... Blood, The Journal of the American Society of Hematology 138 (19), 1885-1895, 2021 | 50 | 2021 |
Complex landscape of alternative splicing in myeloid neoplasms CE Hershberger, DC Moyer, V Adema, CM Kerr, W Walter, S Hutter, ... Leukemia 35 (4), 1108-1120, 2021 | 48 | 2021 |
A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms Y Guan, AD Tiwari, JG Phillips, M Hasipek, DR Grabowski, S Pagliuca, ... Blood cancer discovery 2 (2), 146-161, 2021 | 48 | 2021 |
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 C Saygin, C Hirsch, B Przychodzen, MA Sekeres, BK Hamilton, ... Blood cancer journal 8 (1), 4, 2018 | 44 | 2018 |
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes C Saygin, A Kishtagari, RD Cassaday, N Reizine, I Yurkiewicz, M Liedtke, ... Blood advances 3 (24), 4228-4237, 2019 | 41 | 2019 |
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia H Awada, Y Nagata, A Goyal, MF Asad, B Patel, CM Hirsch, ... Blood advances 3 (3), 339-349, 2019 | 41 | 2019 |